Randomization baseline data on demographic, clinical, COVID related timelines, laboratory variables, and Standard of Care (SOC) drugs in the study groups.
cardiac disorder, hyperlipidemia, Allergic rhinitis, thyroid disorder, chronic lung disease, comorbid disorders
CARDIAC DISORDER, HYPERLIPIDEMIA, ALLERGIC RHINITIS, THYROID DISORDER, CHRONIC LUNG DISEASE
*Statistically significant (P<0.05)NS Not statistically significant (P> = 0.05)a. Student’s ‘t test (normative data) or Chi-Square statistic (categorical data)b. Note- n: number of study participants; SD: standard deviation; AYUSH plus: AYUSH 64 + SOC; BMI: body mass index; ESR: erythrocyte sedimentation rate (Wintrobe method); Other comorbid disorders: hyperlipidemia (2), cardiac disorder (1), chronic lung disease (2), thyroid disorder (5), Allergic rhinitis (3), number of participants in parenthesis; See text for detailsThere were no significant differences between the two study groups for COVID related timelines such as’ onset of symptom to hospital admission’ (-1.34 to 1.72),’ hospital admission to randomization’ (-0.17 to 0.39), and ‘symptom onset to randomization’ (-1.08 to 1.98); 95% CI of the difference (days) between means is shown in parenthesis (A list of SOC drugs is shown in 62.8% of the participants showed radiographic abnormalities in the chest which were consistent with COVID-19 and classified as mild or moderate by the radiologist (See, Table S5.6 in 